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Background: Both genetic and epigenetic factors influence the development and progression of epithelial ovarian
cancer (EOC). However, there is an incomplete understanding of the interrelationship between these factors and
the extent to which they interact to impact disease risk. In the present study, we aimed to gain insight into this
relationship by identifying DNA methylation marks that are candidate mediators of ovarian cancer genetic risk.
Methods: We used 214 cases and 214 age-matched controls from the Mayo Clinic Ovarian Cancer Study. Pretreatment,
blood-derived DNA was profiled for genome-wide methylation (Illumina Infinium HumanMethylation27 BeadArray) and
single nucleotide polymorphisms (SNPs, Illumina Infinium HD Human610-Quad BeadArray). The Causal Inference Test
(CIT) was implemented to distinguish CpG sites that mediate genetic risk, from those that are consequential or
independently acted on by genotype.
Results: Controlling for the estimated distribution of immune cells and other key covariates, our initial
epigenome-wide association analysis revealed 1,993 significantly differentially methylated CpGs that between
cases and controls (FDR, q < 0.05). The relationship between methylation and case-control status for these 1,993
CpGs was found to be highly consistent with the results of previously published, independent study that consisted
of peripheral blood DNA methylation signatures in 131 pretreatment cases and 274 controls. Implementation of
the CIT test revealed 17 CpG/SNP pairs, comprising 13 unique CpGs and 17 unique SNPs, which represent potential
methylation-mediated relationships between genotype and EOC risk. Of these 13 CpGs, several are associated with
immune related genes and genes that have been previously shown to exhibit altered expression in the context of
cancer.
Conclusions: These findings provide additional insight into EOC etiology and may serve as novel biomarkers for
EOC susceptibility.
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Epithelial ovarian cancer (EOC) is the fifth leading cause
of cancer death among women in the United States and
the most deadly among gynecologic malignancies. In
2013 it is estimated that 22,240 new cases of EOC will
be diagnosed [1], making it one of the most common gy-
necologic malignancies. Along with the physical burdens* Correspondence: bfridley@kumc.edu
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ing that EOC accounts for upward of 5.1 billion dollars
annually; rendering this disease as one of the most
expensive cancers to treat [3]. The enormous physical,
societal, and economic burdens associated with EOC
along with the current lack of success in the early diagno-
sis of this disease, underscore the urgent need of studies
aimed toward understanding the molecular basis of EOC
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that are not based on differences in the underlying DNA
sequence, are potentially reversible, and are generally
stably maintained during cell division. Epigenetic marks
such as DNA methylation (DNAm) of cytosine residues in
the context of CpG dinucleotides, have been extensively
characterized in EOC tumor tissue and have been shown
to differ between histological subtypes of ovarian cancer
[4], associate with patient clinical outcomes including sur-
vival time [5] and progression [6], and have led to identifi-
cation of inherited variants in HNF1B (hepatocyte nuclear
factor 1 homeobox B) as a subtype-specific susceptibility
gene [7]. Despite the obvious relevance of investigating
tumor-derived DNAm signatures for understanding EOC
risk and prognosis, it also is clear that tumors do not de-
velop as isolated phenomenon in their target tissue, but
instead result from altered processes affecting neighboring
cells and tissues, including the immune system. Thus,
alterations DNAm profiles measured in peripheral blood
may be useful not only in understanding the carcinogenic
process and response to environmental insults, but may
also provide critical insights in a systems biological view
of tumorigenesis. Recent work has begun to translate
these findings to clinically useful endpoints by examin-
ing the relationship between DNAm alterations and
cancer risk [8-11], including ovarian cancer [12]. Yet,
the retrospective nature of such studies and the assess-
ment of DNAm peripheral blood leukocytes present
significant challenges in the interpretation of the re-
sults; in particular, (a) the extent to which the identified
methylation marks are consequential or are causal/me-
diators of disease risk and (b) potential for confounding
due to heterogeneity in the underlying population of
cells used for methylation assessment [13-15].
These challenges have served to motivate the applica-
tion of novel analytical approaches for retrospective
studies of DNA methylation that aim to distinguish epi-
genetic marks that are consequential or reflect alter-
ations to the methylome driven by the tumor itself, from
those that are causal or mediate tumor growth and de-
velopment. In particular, a recent case-control study of
rheumatoid arthritis, Liu et al., [16] utilized genotype
data collected on the study subjects to identify methy-
lation marks that fall along the casual pathway from
genotype to disease status. As the potential for con-
founding due to cell heterogeneity represents a major
bottleneck in the interpretation of blood-based studies
of DNA methylation, the authors also applied a recently
developed statistical methodology [13] for estimating the
underlying distribution of cell types across each of the
study samples, enabling them to control for the potential
confounding effects of cell type heterogeneity. The over-
arching paradigm of this work is that genetically driven
alterations in the pattern of DNAm of white blood cellscan result in functional deficits in the normal function-
ing of immune system that modify disease susceptibility.
Here, we speculated that these same might hold true
for EOC risk; that genetically induced changes in the
epigenetic landscape of white blood cells can alter sus-
ceptibility to EOC. Indeed, integrative genomics studies
of other cancers, for example prostate cancer, indicate
that the tumor epigenetic landscape is partly mediated
by genetic differences, which may affect disease pro-
gression [17,18]. Additionally, Genome-wide association
studies (GWAS) in the context of ovarian cancer have
identified 11 common risk alleles [7,19-24], and six of
these are located in homeobox gene clusters (HOXA,
HOXB, and HOXD), homeobox-related genes (HNF1B),
or genes expressed in early progenitor cells (BNC2,
TERT) [20,25,26]; many developmental genes such as
these are silenced by DNAm in differentiated cells and
become aberrantly hypomethylated during tumorigen-
esis [26].
Given the well-established role of genetic variation and
EOC risk and importance of examining DNA methy-
lation in non target tissues, we attempted to leverage
these findings along with the analytical framework ap-
plied in Lui et al. [16], with the goal of gaining better
understanding the epigenetic basis of EOC susceptibil-
ity. Specifically, using blood-derived genome-wide epi-
genetic and genetic data collected on a total of 214 EOC
cases and 214 controls enrolled in the Mayo Clinic
Ovarian Cancer Study, we aimed to distinguish blood-
based DNA methylation markers that are candidates for
mediating EOC genetic risk.
Methods
Study population and sample preparation
This study consisted of 428 women of European ancestry
(214 pre-treatment invasive epithelial ovarian cancer cases
and 214 controls one-to-one matched with EOC cases on
the basis age (within 1-year)) between the ages of 27 and
91 enrolled in the Mayo Clinic Ovarian Cancer Study [20].
Genomic DNA was isolated from whole blood collected
at the time of enrollment, using PureGene DNA iso-
lation reagents (Gentra Systems, Minneapolis, MN),
re-suspended in TE buffer, and stored at -80°C. Samples
were bar-coded with a unique subject identification num-
ber to ensure accurate and reliable sample processing and
storage. Research protocols were approved by the Mayo
Clinic Institutional Review Boards, and all participants
provided written informed consent.
Genotype data
Leukocyte-derived DNA was genotyped with the Illu-
mina 610-quad Beadchip Array™ according to manufac-
turer’s protocol, at the Mayo Clinic Medical Genome
Facility (Rochester, MN) by laboratory personnel blinded
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cedures have been described elsewhere [20,27]. Briefly,
Illumina’s Genome Studio™ software was used to perform
automated genotype clustering and calling. Assays included
duplicates and laboratory controls, which showed sample
concordance of 99.93%, genotype call rate of 99.7%. SNPs
were excluded with call rate <95%, MAF <0.05, Hardy-
Weinberg Equilibrium (HWE) p-value < 10-4, or unre-
solved replicate errors, and samples were excluded with
call rate <95%, ambiguous gender, or predicted less than
80% European ancestry. SNPnexus was used to annotate
the genotyped variants [28-30].
DNA methylation assays
Leukocyte-derived DNA was assayed and underwent QC
procedures at the Mayo Clinic Molecular Genome Facility
(Rochester, MN). Samples were assayed in two batches,
hereafter referred to as Batch 1 (n = 132; 66 cases and
matched control samples) and Batch 2 samples (n = 296;
148 cases and matched control samples). For each sample,
1 μg of genomic DNA was bisulfite modified (BSM) using
the Zymo EZ96 DNA Methylation Kit (Zymo Research,
Orange, CA) according to the manufacturer’s protocol.
Epigenome-wide assessment of DNA methylation was car-
ried out using the Illumina Infinium HumanMethyla-
tion27 BeadChip, which is capable of interrogating the
methylation status >27,000 CpG loci across the genome.
This assay uses bisulfite-treated DNA and two site-specific
probes for each marker, which bind to the associated
methylated and unmethylated sequences. The intensity of
the methylated probe relative to the total probe intensity
(sum of methylated and unmethylated probe intensities)
represents the fractional level of methylation for that spe-
cific site within a sample. Centre d’Etudes du Polymor-
phisme Humain (CEPH) DNA, placental DNA (positive
control) and whole genome amplified (WGA) DNA (nega-
tive control) were also included (n = 9, n = 12 and n = 8,
respectively), as were technical replicates (n = 12). Briefly,
fragmented DNA was hybridized to the BeadChips, which
were then processed through a primer extension and an
immunohistochemistry staining protocol to allow detec-
tion of a single-base extension reaction. Finally, BeadChips
were coated and then imaged on an Illumina iScan.
Analysis included control probes for assessing sample-
independent and sample-dependent performance.
Methylation data pre-processing and quality control
The methylation level of each CpG locus was calculated
in GenomeStudio® Methylation module (v.1.9.0) by com-
paring the ratio of fluorescent signal from the methyl-
ated allele to the sum from the fluorescent signal from
both methylated and unmethylated alleles and scored as
beta values, ranging from 0 (unmethylated) to 1 (methyl-
ated). We first excluded probes that had an rsid, werelocated on the Y chromosome, or were positioned at a
single nucleotide polymorphism (SNPs) (dbSNP build
137), as SNPs at the same site have the potential to con-
found methylation assessment. We also removed CpG
loci that had high beta values in BSM negative controls
(defined as exceeding four standard deviations of the
mean) and those that were detected in <70% of samples
(based on a detection p-value cut-off of 0.05). This left a
total of 25,926 out 27,578 (94%) of probes that passed
QC. The intra-class correlation coefficients, computed
based on beta values among CEPH replicates and for du-
plicate samples, were >0.93, indicating a high degree of
reproducibility in our array. In addition, samples were
excluded if >25% of the probes for that sample had de-
tection p-values that exceeded 1 × 10-5. Following QC,
428 samples remained for analyses; including 132 sam-
ples (66 cases and matched control samples) and 296
samples (148 cases and matched control samples) in
Batch 1 and Batch 2, respectively.
Next, we assessed possible plate/Beadchip/batch ef-
fects visually and through principal component analyses
(PCA) [31,32]. DNAm values were logit-transformed
(i.e., log2(β/1- β)) as in previous studies to obtain the
DNAm M-value for each CpG locus [33,34]. PCA repre-
sents a feature extraction technique where the methyla-
tion data is orthogonally transformed, such that the first
principal component has the largest possible variance
(accounts for maximal amount of variability in the methy-
lation data), and each succeeding component, in turn has
the next highest variance possible. PCA was applied to the
methylation data for each batch separately (n1 = 138 and
n2 = 296, for Batch 1 and Batch 2, respectively) and also to
the combined methylation data for both Batches (n = 428).
The resulting top principal components (those explaining
the maximal proportion of variability in DNAm) were
then examined in terms of their association with technical
aspects concerning the array (i.e., plate/BeadChip), and
batch for the principal components estimated from the
combined methylation data from the Batch 1 and Batch 2
samples. As batch was observed to be a major determinant
of variability in the combined DNAm data (Additional
files 1 and 2), we adjusted for batch-effects by applying the
ComBat normalization method [35] using the R-package
‘sva’. Combat is an empirical Bayes batch adjustment
methodology that uses a location and scale adjustment
for standardizing the mean and variability in methy-
lation levels across batches. This methodology been
shown to perform effectively and efficiently compared
to competing batch/plate-adjustment methodologies
[36,37] and has become an established preprocessing
step for array-based DNA methylation data [38-40].
Following the application of Combat, principal com-
ponents were computed from the batch-adjusted data
and inspected to ensure that batch effects had been
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we observed plate-effects (data not shown). To remove
variability in DNAm due to plate, we fit a linear model
to the logit-transformed methylation values for each
CpG locus and included a fixed effect term for plate.
The logit-transformed locus means were then added
back onto the unstandardized residuals derived from
these models, before back transforming values on the
logit-scale to a 0 to 1 scale.
Technical validation of the methylation array data
As an orthogonal array validation, eight CpGs with a
broad spectrum of percent methylation (range; 0.11-
0.73) and variability (standard deviation; 0.11-0.15) were
assessed using bisulfite pyrosequencing. Ninety-six sam-
ples were tested, including 45 cases and 45 controls, two
samples each of WGA, BSM negative, and control sam-
ples (CpGenome™ Universal Methylated DNA; Millipore
Corporation, Billerica, MA). Primers (Additional file 3)
were designed using the Pyrosequencing Assay Design
Software. Genomic DNA (20-30 ng) was PCR-amplified
using primers, one of which was biotinylated. Briefly, the
incorporated biotinylated amplicon was immobilized on
streptavidin-coated beads used to purify and render
the denatured, single stranded and biotinylated PCR
product. Single stranded DNA was purified using the py-
rosequencing vacuum workstation. The single-stranded
product was annealed to 0.3 μM of the sequencing pri-
mer complementary to the single-stranded template and
placed at 85°C for two minutes, then cooled to room
temperature for five minutes. Pyrosequencing reactions
were performed on Biotage PyroMark MD, and data
were analyzed using PyroMD Software. Percent methyla-
tion was quantified as methylated C to unmethylated C ra-
tio using the Pyro Q-CpG software, which provided
automatic QC for each sample for completion of bisulfite
conversion and estimates of non-converted DNA. The
median Pearson correlation of methylation values between
the array and pyrosequencing assays was 0.88 (Additional
file 3), suggesting high concordance in the methylation
array values and those generated from pyrosequencing.
Cell mixture deconvolution analysis
Recent work has demonstrated substantial differences in
the DNAm signature across different leukocyte subtypes
[13-15] and also differences in white blood cell propor-
tions by EOC case-control status [41-43]. As such, het-
erogeneity in the underlying distribution of white blood
cell types is likely to be a key confounder when examin-
ing the association between DNAm and EOC status.
Using the plate- and batch-adjusted methylation data,
we employed a statistical methodology [13] for inferring
changes in the distribution of leukocytes based on per-
ipheral blood DNAm signatures, in combination with apreviously obtained external reference data set consist-
ing of methylation signatures from purified leukocyte
samples (i.e., B cells, natural killer (NK) cells, CD8+ T
lymphocytes, CD4+ T lymphocytes, monocytes, and
granulocytes) [13,14]. In this approach data obtained
from a target set comprised of DNA methylation pro-
files from a heterogeneous mixture of cell populations
is assumed to be a high-dimensional multivariate sur-
rogate for the underlying distribution of cell types.
Houseman et al. [13], proposed a cell mixture decon-
volution methodology – similar to regression calibra-
tion – that involves the projection of DNA methylation
profiles from the target set onto a reference data set,
which consists of the DNA methylation signatures for
isolated leukocyte subtypes. Under certain constraints,
the cell mixture deconvolution approach can be used to
approximate the underlying distribution of cell propor-
tions within the target data via constrained projection.
Application of this method to our data allowed us to es-
timate the expected difference in cell type proportions
between ovarian cases and controls, as well as to predict
the proportion of the aforementioned leukocyte sub-
types for each of the study samples. In addition, these
methods allowed us to quantify the proportion of total
and systematic variability in peripheral blood DNAm
explained by estimated immune cell composition.
Although this method has been shown to produce ac-
curate and reliable estimates of the underlying distribu-
tion of cell type [44], we additionally investigated the
consistency of our results with an independent study
population. Specifically, we compared our estimates of
the expected difference in cell type proportions between
ovarian cases and controls with the results reported in
Houseman et al. [13]; which consisted of the application
of the cell mixture methodology using blood-derived
methylation data from n = 131 pretreatment EOC cases
and n = 274 controls [12].
Causal inference test (CIT)
In a manner similar to that described in Liu et al. [16],
genotype (G), methylation (M), and phenotype (Y) rela-
tionships were assessed using the causal inference test
(CIT) [45] to classify them as “methylation mediated”,
“methylation consequential” or “independent”. The CIT
is comprised of a series of conditional correlation ana-
lyses that consider the possible directed relationships
between a causal factor (genotype (G)), a potential medi-
ator (methylation (M)) and an outcome (EOC status (Y))
(Figure 1A). In order for methylation (M) to be classified
as a mediator of genetic (G) risk for EOC (Y) the follow-
ing conditions must be met: (1) G and Y are associated,
(2) G is associated with M after adjustment for Y, (3) M
is associated with Y after adjusting for G, and (4) G is in-
dependent of Y after adjusting for M (Figure 1B). When
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Figure 1 Identification of epigenetically mediated genetic risk factors for EOC. (A) Directed acyclic graphs (DAGs) depicting the possible
relationships between a causal factor (G), a potential mediator (M), and an outcome (Y). Top, DAG for the methylation-mediated relationship,
wherein G acts on Y through M. Middle, DAG for the methylation-consequential (reverse causality) relationship, in which changes in M arise as a
consequence of Y. Bottom, DAG for the methylation-independent relationship, wherein G acts on M and Y independently. (B) The four
components of the CIT. (C) Flow diagram illustrating the various filtering steps, and ensuing results, used to identify methylation sites that are
candidates for mediators of genetic risk for EOC.
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G (Figure 1A), there should be no difference in the effect
of G on Y, when conditioning on M. However, when M
mediates the genetic risk for EOC, conditioning on M
should substantially reduce the effect of G on Y [16,45].
The CIT P-value was defined using the intersection-
union framework as the maximum of the component P-
values for the first three of these conditions. G, M, and
Y relationships were considered methylation-mediated
if: the p-value obtained from the fourth condition above
was > 0.05, indicating no statistically significant associ-
ation between G and Y after adjustment for M; and the
CIT P-value was < 0.05. Where appropriate, linear and
logistic regression models were used to examine the four
conditions comprising the CIT.
To ease the computational burden that would ensue
from examining the above conditions for every G, M, and
Y trio (503,502 × 25,926 × 4 total tests), we implementedthe three step filtering procedure described in [16]. In the
first step, the methylation status of each CpG, epigenome-
wide, was examined for its association with Y. In step two,
potential genetic regulators of methylation were identified
by computing the pairwise relationship between each SNP,
genome-wide, and each of CpG sites that were associated
with Y in step 1. The final step involved an examination of
the relationship between Y and each SNP that was identi-
fied as statistically significant in step 2. The general
scheme of this analytic procedure is given in Figure 1C.
Identifying ovarian cancer-associated differentially meth-
ylated CpGs
To discern differentially methylated CpGs between EOC
cases and controls, we fit a series of linear regression
models, which modeled the methylation M-value for each
CpG as a function of ovarian case/control status. Models
were adjusted for the estimated differential leukocyte cell
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current smoking status (yes vs. no), alcohol consump-
tion (never, former, and current), study enrollment year
(1999-2002, 2003, 2004, 2005, and 2006-2007), location
of residence (MN vs. other), parity and age at first birth
(nulliparous, 1-2 at ≤ 20 yrs, 1-2 at > 20 yrs, 3+ at ≤ 20 yrs,
and 3+ > 20 yrs), and the first principal component repre-
senting within-European population sub-structure. Due to
the large number of tests being performed, we corrected
for multiple comparisons by computing the false discovery
rate (FDR) q-value [46].
Identifying genotype-dependent differentially methylated
CpGs
All epigenome-wide statistically significant (FDR q-value <
0.05) ovarian cancer- associated differentially methylated
CpGs were subsequently examined based on their associ-
ation with genotype using an additive minor-allele dosage
model fit to all of the study subjects. Briefly, we used
a series of linear regression models (# ovarian cancer-
associated CpGs × # of SNPs) that modeled methylation M-
values, as a function of the number of minor alleles for a
specific SNP. Genotype-methylation associations were ad-
justed for multiple comparisons by computing the FDR q-
value. A less stringent FDR q-value cutoff of 0.10 was used




The study population considered here consisted of 428
women of European ancestry (214 pre-treatment invasive
EOC cases and 214 controls) between the ages of 27 and
91 enrolled in the Mayo Clinic Ovarian Cancer Study. Of
the EOC cases (n = 214), 114 had tumors of serous hist-
ology (66%), 49 tumors were endometriod (23%), 13 were
clear cell (6%), 5 were mucinous (2%) and 6 (3%) were
other/unknown. Further information on clinical, lifestyle,
and demographic characteristics of the study population is
provided in Table 1 and Additional file 4. In general, base-
line characteristics of EOC cases versus controls were
similar to those estimated based on previous studies of
known risk factors (Additional file 4).
Inferred immune cell subsets differ between ovarian
cases and controls
As DNAm was profiled using genomic DNA from whole-
blood, which is comprised of genetic substrate from va-
rious leukocyte subtypes, the methylation signatures in
our study population represent the aggregate methylation
profile across a complex cellular landscape. To examine
the predicted differences in the major leukocyte compo-
nents of whole blood (i.e., B cells, natural killer (NK) cells,
CD8+ T lymphocytes, CD4+ T lymphocytes, monocytes,and granulocytes) we utilized the cell mixture methodology
of Houseman et al. [13]. This method uses a reference
panel consisting of the DNAm signatures of isolated
leukocyte subtypes to deconvolve the distribution of white
blood cell types when DNAm is profiled in whole blood.
As noted in Figure 2A, several of the estimated cell type
proportions showed statistically significant (p < 0.05) differ-
ences between EOC cases and controls. More importantly,
the relationship between cell type and EOC status was
highly consistent between both batches of samples within
our study population and also with the results reported in
a prior publication [13], which consisted of the application
of the cell mixture methodology to an independent study
population of n = 131 pretreatment EOC cases and n = 274
controls [12]. In particular, granulocyte fractions were
higher in EOC cases, while CD8+ T lymphocyte and CD4+
T lymphocyte, and, to a lesser extent B cell and NK cell
fractions, were lower in EOC cases compared to controls.
These results combined with known methylation dif-
ferences by cell type suggest that it is critical and feasible
to adjust for the underlying distribution of cell types
when investigating the relationship between DNAm and
EOC case/control status. In particular, Figure 2 shows
the epigenome-wide association between DNAm and
EOC status (Batch 1 and 2 samples combined) before
(Figure 2B,D) and after (Figure 2C,E) adjustment for the
estimated cell type proportions, and demonstrates a sub-
stantial reduction in the number of differentially methyl-
ated CpGs by EOC case/control status upon adjustment.
Identifying CpG dinucleotides that mediate genetic risk
for EOC
Case-control studies focused on the identification of pat-
terns of differential DNAm in the context of disease
phenotypes are limited by their retrospective nature and,
therefore, are unable to discriminate between patterns
that are a consequence of the disease and those that are
mediators of disease risk. To filter out consequential epi-
genetic marks in an attempt to understand biology re-
lated to the cause of EOC, we adopted the framework
described by Liu et al. [16] for identifying epigenetic
marks that are candidate mediators of genetic risk for
EOC. To identify instances in which genetic variation
influences risk for EOC by regulating CpG-specific methy-
lation patterns we performed a three-step filtering proced-
ure followed by the Causal Inference Test (CIT) [45]. In
the first filtering step, we conducted an epigenome-wide
association study (EWAS) to identify CpGs differentially
methylated by EOC case/control status. Using a series of
linear regression models that were adjusted the estimated
cell-type proportions and other key covariates, we found
1,993 out of 25,926 (7.7%) CpGs were associated with
EOC case/control status after controlling for multiple
comparisons (FDR, q < 0.05), step 1 Figure 1C, Additional








Control 66 (50.0%) 148 (50.0%) 214 (50.0%)
Case 66 (50.0%) 148 (50.0%) 214 (50.0%)
Age
Mean (SD) 60 (12) 63 (13) 62 (13)
Median 61 65 64
Q1, Q3 50, 69 54, 73 52, 72
Range (33–82) (27–91) (27–91)
Year enrolled
1999–2002 18 (13.6%) 164 (55.4%) 182 (42.5%)
2003 10 (7.6%) 36 (12.2%) 46 (10.7%)
2004 41 (31.1%) 33 (11.1%) 74 (17.3%)
2005 25 (18.9%) 23 (7.8%) 48 (11.2%)
2006–2007 38 (28.8%) 40 (13.5%) 78 (18.2%)
Parity, number of births
Nulliparous 24 (18.2%) 42 (14.2%) 66 (15.4%)
1-2,<=20 yrs 7 (5.3%) 14 (4.7%) 21 (4.9%)
1-2,>20 yrs 31 (23.5%) 84 (28.4%) 115 (26.9%)
3+,<=20 yrs 28 (21.2%) 47 (15.9%) 75 (17.5%)
3+,>20 yrs 40 (30.3%) 95 (32.1%) 135 (31.5%)
Smoking status (current)
No 120 (90.9%) 259 (87.5%) 379 (88.6%)
Yes 10 (7.6%) 19 (6.4%) 29 (6.8%)
State
Other 68 (51.5%) 120 (40.5%) 188 (43.9%)
Minnesota 64 (48.5%) 176 (59.5%) 240 (56.1%)
Alcohol consumption
Never 32 (24.2%) 71 (24.0%) 103 (24.1%)
Current 78 (59.1%) 152 (51.4%) 230 (53.7%)
Former 18 (13.6%) 47 (15.9%) 65 (15.2%)
Histology
Serous 43 (65.2%) 98 (66.2%) 141 (65.9%)
Mucinous 1 (1.5%) 4 (2.7%) 5 (2.3%)
Endometrioid 16 (24.2%) 33 (22.3%) 49 (22.9%)
Clear Cell 4 (6.1%) 9 (6.1%) 13 (6.1%)
Other 2 (3.0%) 4 (2.7%) 6 (2.8%)
Grade
Grade 1 1 (1.6%) 9 (6.1%) 10 (4.7%)
Grade 2 10 (15.6%) 21 (14.2%) 31 (14.6%)
Grade 3 32 (50.0%) 79 (53.4%) 111 (52.4%)
Grade 4 21 (32.8%) 39 (26.4%) 60 (28.3%)
Table 1 Clinical characteristics for the study population
(Continued)
Stage
Stage 1 11 (16.7%) 29 (19.6%) 40 (18.7%)
Stage 2 3 (4.5%) 11 (7.4%) 14 (6.5%)
Stage 3 43 (65.2%) 84 (56.8%) 127 (59.3%)
Stage 4 9 (13.6%) 24 (16.2%) 33 (15.4%)
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the methylation of these 1,993 CpG loci in an independent
study population [12]. Our validation analysis revealed
that 1,603 out of 1,993 CpG loci (80%) were significantly
differentially methylated (FDR; q < 0.05), and of these
1,603 loci, 94% exhibited the same direction of association
(i.e., hyper versus hypomethylated) compared to the results
obtained from our study population (Additional file 5).
Similar to the models fit to our study population, models
fit to the independent data were adjusted for the estimated
distribution of cell types and subject age; however smoking
status, alcohol consumption, parity and population sub-
structure variables were not available in these data and
therefore could not be used for adjustment.
In an attempt to identify CpGs where methylation might
be genetically influenced, we performed a genome-wide
SNP association analysis for each of the 1,993 CpG loci
that were differentially methylated between EOC cases
and controls. Fitting an allelic dosage model to each of
these CpGs and each of 503,502 SNPs, we identified 427
CpG-SNP pairs with genome-wide statistical significance
(FDR; q <0.10) (step 2 Figure 1C, Additional file 6). These
427 CpG-SNP pairs constituted 377 unique SNPs and 185
unique CpGs, and these CpG loci were disproportionately
located in CpG islands (Fisher’s Exact; p = 0.017); CpG-
dense regions present in the promoters of 50%–70% of
human genes. Nonetheless, it is still possible that the
differential patterns of methylation observed for these
185 CpGs are a consequence of EOC or independently
acted on by genotype. To address this concern, we next
examined the association between the 377 unique SNPs
and EOC status. Of the 377 SNPs, we identified 28 that
were significantly associated with EOC status at P < 0.05
(Additional file 7). These 28 SNPs form 28 CpG-SNP
pairs with 19 unique CpGs (step 3 Figure 1C). Imple-
menting the CIT test, we found that the SNP associ-
ation with EOC was attenuated upon adjustment for
methylation for 17 of the 28 CpG-SNP pairs (61%), sug-
gesting mediation (Figure 3). These 17 CpG-SNP pairs
constituted 13 unique CpGs and 17 unique SNPs and
represent potential methylation-mediated relationships
between genotype and EOC risk (step 4 Figure 1C,
Table 2). Information regarding the genomic location
and additional annotation for these CpGs and SNPs is
provided in Additional files 8 and 9, respectively.
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Batch 1 (ncases = 66, ncontrols = 66)
Batch 2 (ncases = 148, ncontrols = 148)
Houseman et al. (2012) (ncases = 131, ncontrols = 274)
A B CUnadjusted for cell type Adjusted for cell type 
D E
Indicates a statistically significant (p < 0.05) 
difference in the estimated cell-type difference 
between EOC cases and controls 
Figure 2 Differential cell distributions in EOC cases. (A) Estimated difference in leukocyte subtypes (i.e., CD8+ T-lymphocytes (CD8T), CD4+
T-lymphocytes (CD4T), natural killer cells (NK), B cells (Bcell), monocytes (Mono), and granulocytes (Gran)) between EOC cases and controls. Bars
reflect the 95% confidence interval for the difference in cell distributions between EOC cases and controls. (B, C) Histograms of P-values obtained
from examining the association between DNAm and EOC case/control status, (B) unadjusted for estimated cell distribution and (C) adjusted for
the estimated cell distribution. Dashed line is the density histogram that is expected if all CpGs were null (not differentially methylated) and the
dotted line is at the height of our estimate of the proportion of null p-values. (D, E) Volcano plots of –log10(q-value) against the estimated difference in
methylation between EOC cases and controls, (D) unadjusted for estimated cell distribution and (E) adjusted for the estimated cell distribution. Red
and blue dashed lines indicate –log10(q = 0.05) and –log10(q = 0.10), respectively. Each model was fit to the combined data from the Batch 1 and 2
samples (n = 428) and were adjusted for age, smoking status, alcohol consumption, study enrollment year, location of residence, parity, and
population substructure.
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among the 17 unique SNPs identified in our analysis
showed that most of the identified SNPs were uncorre-
lated at r2 < 0.05, with the exception of rs1250220 and
rs1250252 located in an intragenic region on chro-
mosome 2q35 and rs6754181, rs2631958, rs2254066,
located in an intron region associated with ALK (ana-
plastic lymphoma receptor tyrosine kinase) (Additional
file 10). The 17 CpG-SNP pairs highlight 13 CpG loci;
all loci correlate with a single SNP or SNP cluster, al-
though cg10636246 located near AIM2 demonstrated
an association with two independent SNPs with dif-
ferent genomic locations (rs11120596 (p = 8 × 10-7) and
rs460380 (p = 5 × 10-7)) (Table 2).
As differences in tumor DNAm, epidemiologic risk
factors, genetic variants, and precursor tissues are knownto exist between the major EOC histologies (serous,
mucinous, endometrioid, and clear cell) [4], we eva-
luated whether the 13 unique methylation mediators
exhibited consistent patterns of methylation in a ca
se-only analysis across EOC subtypes. With the ex-
ception of cg25553916 located in the promoter region
of FLJ22318 (required for meiotic nuclear division 5
homolog B), which showed increased methylation in
mucinous cases (p = 0.006), the methylation levels of
the 12 remaining CpG loci were not statistically significant
different across the histologies of EOC (Additional file 11).
Interestingly, this locus was the only one among the
13 that did not exhibit the same direction of association
with EOC comparing our results to those from the
Teschendorff et al. [12] data (Table 2 and Additional
file 5).
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Figure 3 Genotype-dependent candidate CpGs that mediate genetic risk for EOC. (Left) Plot depicting the DNAm status of cg10061138,
associated with gene STAB1, between (A) EOC cases and controls and by genotype at SNP rs11884397 (B). Red lines denote the median methylation
levels. (C) Percentage of EOC cases by the number of minor alleles for SNP rs11884397. (D) Coefficient (β) reflects the log-odds of EOC for a one-unit
increase in the number of minor alleles for SNP rs11884397 with and without adjustment for the methylation levels of cg10061138. Bars represent the
95% CI for the estimate of the log-odds (i.e., β). (E-H) Density plots of DNAm by genotype (AA = green, Aa = red, and aa = blue) for four EOC–associated
CpGs; solid lines indicate the methylation distribution for EOC cases and dotted lines indicate the methylation distribution for controls.
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Attempts aimed at distinguishing causal methylation marks
from those that are merely a consequence of disease are
critical for elucidating the biological mechanisms under-
lying this disease. Previous analyses of genetic regulators of
methylation and expression levels have revealed three-way
causal relationships, where the prevailing model is one in
which genetic variation influences methylation that in turn
influences expression levels. The idea that DNA methy-
lation levels at specific loci are under genetic control has
gained traction in recent years, bolstered by the results
obtained from comparing patterns of DNA methylation
between monozygotic and dizygotic twins [47]. Here, we
aimed to leverage these findings in an attempt to filter out
epigenetic marks resulting from disease, focusing our at-
tention on the identification of epigenetic marks that are
potential mediators of genetic risk for EOC. Not only are
such analyses critical for our understanding of EOC patho-
genesis, but the genotype-methylation markers identified
through such efforts may further enhance the growing
library of risk-associated biomarkers for EOC.
Associations between genetic variation with expression
and methylation levels have been identified in several or-
ganisms [48,49] and tissue types [50]. While recent workhas demonstrated both local (cis) and distal (trans) associa-
tions of genetic variation with methylation levels [51-53],
little is known about the precise biological mechanisms by
which genetic variants modify DNA methylation. All of the
methylation-genotype pairs identified in our analysis in-
dicated trans regulation, or distant regulation effects.
Although none of the 17 SNPs identified in our analysis
have been previously identified as reaching genome-wide
statistical significance in GWAS of ovarian cancer, of par-
ticular importance was the identification of ALK as a po-
tential regulator of CpG-specific DNAm and genetic risk
marker for EOC. This gene encodes a receptor tyrosine
kinase belonging to the insulin receptor superfamily, and
has been found to be rearranged, mutated, or amplified in
a series of human cancer tumorigenesis [54-56]. Recent
work has demonstrated methylation induced silencing of
IL-2Rγ expression in in T-cell lymphoma cells expressing
NPM-ALK kinase [57], which originates from fusion of the
nucleophosmin (NPM) and the membrane receptor ana-
plastic lymphoma kinase genes. IL-2Rγ is shared by re-
ceptors for several cytokines that play key roles in the
maturation and growth of normal CD4+ T lymphocytes
and other immune cells. Thus, it is possible that genetic
variation in ALK contributes to epigenetic modifications
Table 2 CpG sites that were identified as potential mediators of genetic risk for EOC (CIT p < 0.05)
CpGs associated with EOC SNPs associated with CpGs
CpG Meth diff P-value
(M vs Y)






cg03718677 -0.08 4.60E-03 TMOD4 1 149414890 rs1250220 2 216320050 2.30E-07 0.023 0.023
cg03718677 -0.08 4.60E-03 TMOD4 1 149414890 rs1250252 2 216313591 1.70E-07 0.029 0.029
cg09822001 0.11 5.50E-04 APOA1BP 1 154827958 rs2919303 8 62214493 1.50E-07 0.027 0.027
cg10636246 -0.11 2.70E-04 AIM2 1 157313597 rs11120596 1 215850817 7.60E-07 0.002 0.002
cg10636246 -0.11 2.70E-04 AIM2 1 157313597 rs460380 21 46028864 5.30E-07 0.01 0.01
cg13721560 0.07 7.90E-03 LRPPRC 2 44076072 rs2289840 3 124181739 9.40E-08 0.041 0.041
cg10061138 -0.09 8.30E-04 STAB1 3 52504125 rs11884397 2 23885388 3.10E-07 0.002 0.002
cg25086702 0.1 1.70E-03 HMGB2 4 174492134 rs11210834 1 43787437 7.10E-08 0.048 0.048
cg24136586 0.1 5.50E-03 ATG10 5 81304122 rs3800524 6 168302015 1.80E-06 0.034 0.034
cg01495509 0.08 5.30E-03 KCNMB1 5 169748956 rs4457945 15 54608127 2.20E-08 0.019 0.019
cg25553916 0.06 6.90E-04 FLJ22318 5 177491361 rs2254066 2 29889019 2.60E-07 0.003 0.003
cg25553916 0.06 6.90E-04 FLJ22318 5 177491361 rs2631958 2 29958841 7.10E-07 0.009 0.009
cg25553916 0.06 6.90E-04 FLJ22318 5 177491361 rs6754181 2 29966380 3.10E-07 0.003 0.003
cg19436567 0.12 1.50E-04 ARID1B 6 157141067 rs12362925 11 16875419 7.80E-08 0.029 0.029
cg08142684 0.13 2.70E-04 TCP1 6 160129858 rs9792311 8 123940585 7.40E-07 0.023 0.023
cg05109049 0.09 5.30E-03 EVI2B 17 26665459 rs2294405 6 99292136 1.60E-06 0.013 0.013
cg00021527 0.09 5.20E-03 TAF15 17 31160293 rs10488500 7 76841259 2.50E-07 0.046 0.046
M: Methylation, G: Genotype, Y: EOC status.
Methdiff: Difference in the methylation M-value between EOC cases minus controls, adjusted for the estimated distribution of cell types, age, smoking status,
alcohol consumption, study enrollment year, location of residence, parity and age at first birth, and the first principal component representing within-European
population sub-structure.
Gene: Denotes the nearest gene for the given CpG site.
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the exact biological mechanisms by which ALK exerts an
influence on DNA methylation is unclear.
It is also compelling that the predicted distribution of
immune cell subsets in our data, which showed in-
creased myeloid derived cell types (e.g., monocytes and
granulocytes) and decreased lymphocytes (e.g., CD8+ T
lymphocytes, CD4+ T lymphocytes, B cells, and natural
killer cells) between EOC cases and controls, mimicked
the results obtained when applying the cell mixture
methodology to an independent study population. The
relationship between predicted cell type distributions
and cancer status are consistent with previous literature,
where it has been demonstrated that EOC cases have
decreased B and T-lymphocyte fractions [41-43] and
increases in neutrophil granulocytes [43]. While modest
variation was observed in the estimated cell type dif-
ferences between EOC cases and controls between the
different study populations, particularly for CD8+ T-
lymphocytes, this is not entirely unexpected given dif-
ferences in the distribution of ovarian cancer histological
subtypes between the study populations (Table 1;
Teschendorff et al. [12]) and that variation in host im-
mune responses to EOC has been shown to vary by
histological subtype [58].Our analysis identified cg25086702 as a potential me-
diator of genetic risk for EOC. This particular locus re-
sides in CpG island region located in HMGB2 (high
mobility group protein 2) and was found to be hyper-
methylated in EOC in the present analysis (β = 0.10, 95%
CI [0.04, 0.16]). High mobility group box (HMGB) pro-
teins are ubiquitous, abundant nuclear proteins with di-
verse functions in the cell. HMGB1 and HMGB2 are the
main members of the HMGB protein family and their
overexpression has been observed in numerous human
malignancies, including hepatocellular [59], skin squa-
mous cell [60], prostate [61], gastrointestinal [62,63]
breast [64,65], and bladder carcinomas [66]. Addition-
ally, a recent report demonstrated increased expression
of HMGB2 in invasive EOC tumors compared to EOC
tumors with low malignancy potential [67]. However,
many of the results demonstrating HMGB2 overexpres-
sion were based on measurements derived from tumor
tissue, and far less is known about the implications of
dysregulated HMGB2 expression in peripheral blood
leukocytes and its role in cancer risk. While it is possible
that our observation of increased CpG island methyla-
tion of HMGB2 in EOC cases is due to the methylation
signature arising from circulating tumor cells (CTCs),
this is unlikely as CTCs would be expected to comprise
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[68], and thus contribute insignificantly to the overall
methylation signatures analyzed. Also, given the role CpG
island hypermethylation on gene silencing and the numer-
ous reports of HMGB overexpression in tumor tissue, we
might expect to see the opposite results (i.e., CpG island
hypomethlation of HMGB2) if in fact, CTCs were driving
force behind the methylation signals detected here. An al-
ternative explanation for these findings is motivated by
the role of HMGB1, a closely related gene, in immune
response in adult peripheral blood. HMGB1 recruits in-
flammatory cells and activates innate immune cells. Fur-
thermore, after being secreted by activated macrophages
or its release from necrotic cells, HMGB1 regulates adap-
tive immunity [69-71]. Thus, CpG island hypermethyla-
tion induced silencing of HMGB1 and possibly other
HMGB genes, may compromise the immune system, pro-
moting tumor development and progression.
Our analysis also identified cg05109049 (β = 0.09, 95%
CI [0.03, 0.16]), associated with EVI2B (Ecotropic Viral
Integration Site 2B Protein), as a potential mediator of
genetic risk for EOC. EVI2B is expressed in peripheral
blood mononuclear cells, fibroblasts, and bone marrow
and blood-based overexpression of this gene was recently
reported in postoperative relapse of colorectal cancer [72].
Another notable discovery from our analysis was hyper-
methylation of cg00021527 (β = 0.09, 95% CI [0.03, 0.15]),
residing in a CpG Island region located in the gene TAF15
(TATA box-binding protein-associated factor 2 N 68 kDa),
which together with FUS (fused in sarcoma) and EWS
(Ewing sarcoma breakpoint 1), constitute the FET protein
family. The FET-proteins are involved in transcriptional
regulation and RNA processing, and FET-gene deregula-
tion is associated with development of cancer. In particu-
lar, a recent report demonstrated that TAF15 knockdown
affects the expression of a large subset of genes, including
many involved in cell cycle and cell death [73]. Together,
these findings highlight the biological relevance of the
methylation sites identified in our investigation and their
potential role in the pathogenesis of EOC.
There are several noteworthy limitations to the present
study. First, the relatively small sample size and large
number of genotype/methylation markers, reduces our
statistical power for detecting genotype/methylation asso-
ciations. To address the burden of multiple comparisons
arising from the large number of genotype/methylation
markers, we employed an analytical strategy that is based
on a series of filtering steps, resulting in many fewer over-
all tests than an analysis considering all possible genotype,
methylation, and phenotype combinations. Further, while
Illumina Infinium HumanMethylation27 BeadChip pro-
vides an efficient solution for surveying genome-wide
DNA methylation profiles, the lower coverage and scope
of this array compared to more recent array technologies,e.g., Illumina Infinium HumanMethylation450 BeadChip,
may have limited our ability for detecting methylation me-
diators of EOC genetic risk.
With regard to our sample size, efforts to replicate the
analysis described here using a larger group of study
subjects as both a validation of our existing results, and
to identify additional methylation sites that mediate
genetic risk for EOC is ongoing research by our group.
Moreover, we additionally evaluated the results of our
EWAS analysis using a previously published data set, which
consisted of whole-blood derived methylation data –
assayed using the same array technology – collected from
pre-treatment EOC cases and controls. Unlike our data,
genotypic information was not available on those subjects,
preventing a complete validation of the genotype-me
thylation pairs identified here. However, the fact that 12
of the 13 (92%) CpGs representing potential methylation-
mediated relationships between genotype and EOC risk
demonstrated the same direction of association with EOC
status is encouraging and serves as motivation for the con-
tinued and future study of these markers.
A second consideration of this work involves the po-
tential for confounding based on interpersonal variability
the distribution of cell types used in assessing DNA
methylation. While previous reports involving blood-
based assessment of DNA methylation have controlled
for cell mixture using complete-blood cell count (CBC)
measurements [74,75], such measurements are not cap-
able of distinguishing between different lymphocyte
subtypes and may be an oversimplification of the com-
plexity and variability in circulating immune cells. Here,
we employed a recently developed statistical method for
predicting the distribution of the major leukocyte com-
ponents of whole blood, followed by their inclusion as
additional covariates in our methylation association ana-
lyses. It should be noted that the cell type predictions
obtained using this approach are themselves estimates
and therefore subject to uncertainty. Computationally
efficient statistical approaches that facilitate the propaga-
tion of this uncertainty into locus-specific differential
methylation analyses are urgently needed and represent
an opportunity for future methodological work.
A limitation of EWAS aimed toward understanding
the molecular basis of complex phenotypes over conven-
tional GWAS, is that the methylation sites identified
from EWAS may be a consequence of the disease or due
to treatment, rather than true biomarkers of disease risk.
We attempted to address this limitation by focusing our
analysis on pre-treatment EOC cases and through the
implementation of a statistical mediation framework that
was recently shown to be an effective tool in the analysis
of data arising from EWAS [16]. We do however note that
in focusing on the identification of candidate methylation
mediators of EOC genetic risk, it is possible, and likely,
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sed using our analytical strategy. Along these lines, there
is an urgent need for studies involving the investigation
of prospectively collected methylation profiles and subse-
quent risk of EOC, such as that carried out in a recent
study of breast cancer risk [76]. It should be acknowledged
that, as in all case-control studies, it is not possible to
establish causality on the basis of purely retrospective ob-
servational data. With this in mind, our findings can be
viewed as a basis for hypotheses, providing a starting point
for future mechanistic studies and studies focused on their
validation in independent study populations.
Conclusions
Overall, this study contributes to the growing archive of
integrative genomics studies by exploring the relationship
between genetics and epigenetics as they relate to EOC
risk. Our analysis identified 17 CpG/SNP pairs, compris-
ing 13 unique CpGs and 17 unique SNPs, which represent
potential methylation-mediated relationships between ge-
notype and EOC risk. These findings provide additional
insight into EOC etiology and may serve as novel bio-
markers for EOC susceptibility. Future work is needed to
independently validate the genotype-methylation markers
discovered here and to elucidate their functional role.
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